Ranked 118th Fastest Growing Company in North America

在北美排名第118的增长最快的公司

Ranked 23rd Fastest Growing Life Sciences Company

排名第23的生命科学公司增长最快

DENVER, CO / ACCESSWIRE / November 8, 2023 / Aytu BioPharma, Inc. (the Company or 'Aytu') (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced, for the third year in a row, it was included on the Deloitte Technology Fast 500™, ranking 118th among North American companies and 23rd among life sciences companies..

丹佛，CO/ACCESSWIRE/2023年11月8日/Aytu BioPharma，Inc。（公司或'Aytu'）（纳斯达克股票代码：Aytu），一家专注于商业化新型治疗药物的制药公司，今天宣布连续第三年它被列入Deloitte Technology Fast 500™, 在北美公司中排名第118，在生命科学公司中排名第23。。

Now in its 29th year, the Deloitte Technology Fast 500 recognizes the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America. The 2023 Technology Fast 500 rankings are based on percentage of revenue growth from 2019 to 2022.

Deloitte Technology Fast 500现在已经进入第29年，它承认北美增长最快的技术，媒体，电信，生命科学，fintech和能源科技公司。2023年Technology Fast 500排名基于2019年至2022年的收入增长百分比。

In fiscal 2023, Aytu generated total net revenue of $107.4 million, an increase of 11% compared to fiscal 2022, driven by a 21% increase in the Company's prescription products.

在2023财年，Aytu产生的总净收入为1.074亿美元，与2022财年相比增长了11%，这是由于公司处方产品增长了21%。

'We are honored to once again be recognized as a member of the prestigious 2023 Deloitte Technology Fast 500 list of most rapidly growing companies,' commented Josh Disbrow, Chief Executive Officer of Aytu BioPharma. 'I'm proud to congratulate the entire Aytu BioPharma team who played such an integral part in driving our continued growth.

Aytu BioPharma首席执行官Josh Disbrow评论说：“我们很荣幸再次被公认为2023年Deloitte Technology Fast 500最快速增长公司名单的成员。”我很自豪祝贺整个Aytu生物制药团队在推动我们持续增长方面发挥了不可或缺的作用。

I look forward to building on the progress made at Aytu over the past year as we maintain our focus on growing our Rx business, generating positive Adjusted EBITDA and net income, and driving shareholder value.'.

我期待着在过去一年中在Aytu取得的进展，因为我们一直专注于发展我们的Rx业务，产生积极调整的EBITDA和净收入，以及推动股东价值。

'Each year I look forward to reviewing the progress and innovations of our Technology Fast 500 winners as these companies truly demonstrate how important new ideas are to progressing our society and the world, especially during difficult times,' said Paul Silverglate, vice chair, Deloitte LLP and U.S.

“每年我都期待回顾我们的技术快速500名获奖者的进步和创新，因为这些公司真正展示了新想法对我们的社会和世界的进步是多么重要，特别是在困难时期，”副主席Paul Silverglate说，Deloitte LLP和美国。

technology sector leader. 'While software and services and life sciences continue to dominate the top 10, I'm encouraged to see other categories making their mark. Congratulations to all the winners who show us how creativity, hard work and perseverance can lead to success.'.

技术部门负责人虽然软件和服务以及生命科学继续占据前十名，但我鼓励您看到其他类别的标志。祝贺所有向我们展示创造力，辛勤工作和毅力如何取得成功的获奖者。

About Aytu BioPharma, Inc.

关于艾图生物制药股份有限公司。

Aytu BioPharma is a pharmaceutical company commercializing a portfolio of commercial prescription therapeutics. The Company's prescription products include Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), Karbinal® ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency.

Aytu BioPharma是一家将商业处方疗法组合商业化的制药公司。该公司的处方产品包括Adzenys XR-ODT®（安非他明）缓释口腔崩解片（见完整的处方信息，包括盒装警告）和Cotempla XR-ODT®（哌醋甲酯）缓释口腔崩解片（见完整的处方信息，包括盒装警告）用于治疗注意力缺陷多动障碍（ADHD），Karbinal®ER（马来酸卡宾诺明）是一种缓释抗组胺药混悬液，适用于治疗多种过敏性疾病，Poly-Vi-Flor®和Tri-Vi-Flor®是两种互补的氟化物处方维生素产品系列，可用于婴儿和氟化物缺乏儿童。

To learn more, please visit aytubio.com..

要了解更多信息，请访问aytubio.com。。

Forward-Looking Statement

前瞻性声明

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. All statements other than statements of historical facts contained in this press release, are forward-looking statements.

本新闻稿包括1933年“证券法”第27A条（经修订）和1934年“证券交易所法”第21E条或“交易所法”含义内的前瞻性声明。本新闻稿中包含的除历史事实陈述以外的所有陈述均为前瞻性陈述。

Forward-looking statements are generally written in the future tense and/or are preceded by words such as ''may,'' ''will,'' ''should,'' ''forecast,'' ''could,'' ''expect,'' ''suggest,'' ''believe,'' ''estimate,'' ''continue,'' ''anticipate,'' ''intend,'' ''plan,'' or similar words, or the negatives of such terms or other variations on such terms or comparable terminology.

前瞻性陈述通常用未来时态写成和/或前面跟着诸如“may”，“will”，“will”，“should”，“prediction”，“can”，“expect”，“建议，''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''。

All statements other than statements of historical facts contained in this press release, are forward-looking statements. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. We also refer you to (i) the risks described in ''Risk Factors'' in Part I, Item 1A of Aytu's most recent Annual Report on Form 10-K and in the other reports and documents the Company files with the Securities and Exchange Commission..

本新闻稿中包含的除历史事实陈述以外的所有陈述均为前瞻性陈述。这些陈述只是预测，可能会导致实际事件或结果出现重大差异的风险和不确定性。我们还请您提及（i）Aytu最新年度报告第10-K表第一部分第1A项“风险因素”中描述的风险，以及其他报告和公司档案与证券交易委员会。。

Contacts for Investors:

投资者联系方式：

Mark Oki, Chief Financial Officer

首席财务官Mark Oki

Aytu BioPharma, Inc.

艾图生物制药股份有限公司。

moki@aytubio.com

moki@aytubio.com

Robert Blum or Roger Weiss

Robert Blum或Roger Weiss

Lytham Partners

Lytham Partners

AYTU@lythampartners.com

AYTU@lythampartners.com

SOURCE: Aytu BioPharma, Inc.

照片：艾图生物制药股份有限公司。

View source version on accesswire.com:

在AccessWire.com上查看源版本：

https://www.accesswire.com/801016/aytu-biopharma-ranked-among-fastest-growing-companies-in-north-america-on-deloittes-technology-fast-500tm-for-third-consecutive-year

https://www.accesswire.com/801016/aytu-biopharma-ranked-among-fastest-growing-companies-in-north-america-on-deloittes-technology-fast-500tm-for-third-consecutive-year